Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
March 19, 2018 16:30 ET
|
Apellis Pharmaceuticals, Inc.
- Initiation of Phase 3 Programs in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for 2018; Phase 2 Proof-of-Concept (POC) Data Anticipated in Autoimmune Hemolytic...
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
February 23, 2018 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
February 22, 2018 08:44 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 02, 2018 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
December 20, 2017 17:30 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Ma., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer
December 19, 2017 10:16 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) at Annual Scientific Assembly of the International PNH Interest Group (IPIG)
December 08, 2017 16:34 ET
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals Announces Closing of its Initial Public Offering
November 13, 2017 16:05 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to...
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 08, 2017 21:38 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to...
Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
December 02, 2016 08:00 ET
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present...